IL-27 Alpha antibody | H08-5C8
IL-27 has broad range of pro- and anti-inflammatory properties, mediating its effects via its gp130-associated cytokine receptor and JAK/STAT signalling cascades. It can alter T helper cell development, suppress T-cell proliferation, stimulate cytotoxic T-cell activity, induce isotype switching in B-cells and has diverse effects on innate immune cells. In vivo, it is reported to play an important role in immune regulation, as mice with defects in IL-27 or its receptor display enhanced immune responses (Batten & Ghilardi 2007).
- Target Species
- Product Form
- Purified IgG - liquid
- Purified IgG prepared by affinity chromatography on Protein G from ascites
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
- 0.09% Sodium Azide (NaN3)
- NS0-derived recombinant human IL-27
- Approx. Protein Concentrations
- IgG concentration 1.0 mg/ml
- Fusion Partners
- Spleen cells from immunised BALB/c mice were fused with cells of the mouse SP2/0 myeloma cell line
- Store at +4oC or at -20oC if preferred.
Storage in frost-free freezers is not recommended.
This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
- 18 months from date of despatch
- Entrez Gene
- GO Terms
- GO:0005125 cytokine activity
- GO:0005615 extracellular space
- GO:0006954 inflammatory response
- GO:0042129 regulation of T cell proliferation
- GO:0045078 positive regulation of interferon-gamma biosynthetic process
- GO:0045087 innate immune response
- GO:0045523 interleukin-27 receptor binding
- GO:0045625 regulation of T-helper 1 cell differentiation
- GO:0050688 regulation of defense response to virus
- For research purposes only
Applications of IL-27 Alpha antibody
|Application Name||Verified||Min Dilution||Max Dilution|
Secondary Antibodies Available
Product Specific References
Batten, M. & Ghilardi, N. (2007) The biology and therapeutic potential of interleukin 27
J Mol Med (Berl). 85: 661-72.